for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Oncogenex says phase 3 ENSPIRIT trial of custirsen in non-small cell lung cancer did not meet primary endpoint

Oct 13 (Reuters) - Oncogenex Pharmaceuticals Inc :

* Oncogenex announces results from the phase 3 ENSPIRIT trial of custirsen in non-small cell lung cancer

* Oncogenex Pharmaceuticals Inc - trial did not meet primary endpoint

* Oncogenex Pharmaceuticals -continuing to work with mts health partners who has been advising co in exploration of strategic alternatives since mid-August Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up